Activity provided by the American Epilepsy Society
Recording date: July 20, 2020
Activity Launch date: August 19, 2020
Expiration date: August 19, 2023

Please review all activity information below. To receive credit for this activity you must view the presentation and complete the evaluation.

Overview
Seizure rescue medications are an important part of a seizure rescue plan. The Webinar will focus on why rescue medications may be used and which patients may benefit most from these medications. With several new products now available, a review of various seizure rescue medications will be included in the presentation. It is important that patients and caregivers understand how to use these medications appropriately and safely. Recommendations for patient and caregiver counseling will be included. The Webinar will conclude with a question and answer discussion with the presenters. The goal of this Webinar will be to increase understanding and effective use of seizure rescue medications.

Target Audience
Physicians, APPs, Clinicians, Fellows/Trainees, Nurses, and Pharmacists

Learning Objectives
Following participation in this activity the learner should be able to:

• Utilize an understanding of seizure rescue medications in identifying patients who may benefit from use of rescue medications.
• Appropriately select a seizure rescue medication and route of administration from available options.
• Effectively educate patients and caregivers on the use of seizure rescue medications.

Disclosure Policy
It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.

Planning Committee, Faculty, Reviewers' Disclosures of Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with an ineligible company. Unless otherwise indicated (*), none of the planners or faculty of this activity have any financial relationships to disclose. All relevant financial relationships with ineligible companies have been mitigated. The following individuals contributed to this activity’s content.

Planning Committee and Faculty
Timothy E. Welty, PharmD, Drake University, Des Moines, Iowa

Tyler E. Gaston, MD, University of Alabama Birmingham, Birmingham, Alabama
Dr. Gaston has disclosed the following relevant relationships:
Consulting fees from WebMD/Medscape and Versar, Inc.; Membership on advisory committees/boards, review panels for WebMD/Medscape; Salary support from Department of Defense/Ocean State Institute and from State of Alabama

Jon A. Cokley, PharmD, Texas Children’s Hospital, Houston, Texas

Jeffrey D. Kennedy, MD, University of California Davis, Davis, California

Linda S. Allen, BSN, RN, Froedtert Hospital/Medical College of WI, Milwaukee, Wisconsin
Ms. Allen has disclosed the following relevant relationships:
Honoraria from UCB Financial


CME Reviewer
Jay Salpekar, MD, Kennedy Krieger Institute,Baltimore, MD
Dr. Salpekar has disclosed the following relevant relationships:
Lundbeck: Investigator initiated study- research funding to institution only; contracted research

American Epilepsy Society Staff Planners
Joy Keller, MS, RD, MSLIS
Penny Dacks, PhD
Cristina Graham, BS

Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards of Integrity and Independence in Accredited Continuing Education, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.

Accreditation
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

For more information regarding contact hours, please call American Epilepsy Society 312.883.3800 or education@aesnet.org.

Credit Designation
The American Epilepsy Society designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificate
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.

Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

Disclaimer
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.